retatrutide glp-1 gip glucagon agonist Retatrutide: The triple powering superior fat loss. + + = up to 24% body weight reduction in trials. Clinical results. Real transformation. #Retatrutide #GLP1 #FatLoss" Synedica Retatrutide | Triple Agonist

160,161 For example, HM15211, a triple agonist developed by Hanmi Pharmaceutical in South Korea that activates GLP-1R, GIPR and GCGR has entered early clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH)

Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM

Figure 33: Photograph of Jean-Pierre Raufman, credit: University of Maryland and photograph of Jonn Eng, credit: University of Buffalo

& Holzhausen, H

Cohorts were balanced on covariates, including demographics, medications, diagnoses, and procedures, using propensity score matching (PSM)

Note: Market size and forecast figures in this report are generated using Mordor Intelligences proprietary estimation framework, updated with the latest available data and insights as of January 2026